Leukotriene receptor antagonists in the treatment of bronchial asthma: Consensus agreement “Bronchial Asthma and LEukoTriene receptor antagonists (BALET)”

封面
  • 作者: Avdeev S.1,2, Geppe N.1, Ilina N.3, Demko I.4, Zhestkov A.5, Zaitseva O.6, Kondyurina E.7, Kukes I.8, Kurbacheva O.3, Malakhov A.1, Mizernitsky Y.9, Nenasheva N.10, Pampura A.9,10, Revyakina V.11
  • 隶属关系:
    1. First Sechenov Moscow State Medical University (Sechenov university)
    2. Pulmonology scientific Research Institute under Federal Medical and Biological Agency of Russian Federation
    3. National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia
    4. Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
    5. Samara State Medical University
    6. Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
    7. Novosibirsk State Medical University
    8. International Association of Clinical Pharmacologists and Pharmacists
    9. The Russian National Research Medical University named after N.I. Pirogov
    10. Russian Medical Academy of Continuous Professional Education
    11. Federal Research Center of Nutrition, Biotechnology and Food Safety
  • 期: 卷 20, 编号 2 (2023)
  • 页面: 130-142
  • 栏目: Clinical practice guidelines
  • URL: https://journals.rcsi.science/raj/article/view/253516
  • DOI: https://doi.org/10.36691/RJA7530
  • ID: 253516

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Under the auspices of the Russian Association of Allergists and Clinical Immunologists and the Russian Pediatric Respiratory Society, an expert meeting on “Leukotriene receptor antagonists in the treatment of bronchial asthma” was held.

Asthma is a common noncommunicable chronic disorder of the airways, characterized by variable and recurring symptoms, airflow obstruction, bronchial hyper-responsiveness, and underlying inflammation.

The creation and widespread use of inhaled corticosteroids and other innovative classes of drugs for treating bronchial asthma have remarkably affected the ability to achieve control over the course of the disease. Regardless, in most European countries, more than half of patients with bronchial asthma have suboptimal disease control. Recently, a class of leukotriene receptor blockers that contribute to the suppression of chronic allergic inflammation in patients with asthma has been actively studied. The majority of studies confirmed the usefulness of montelukast as monotherapy and as an add-on therapy to inhaled corticosteroids in mild to moderate asthma across all age groups. However, experts noted that in practical medicine, healthcare providers continuously inquire about the effectiveness and safety of this class of medicines in patients with bronchial asthma.

In this consensus document, the experts considered the importance of providing an answer to several topical questions regarding the use of antileukotriene therapy in clinical practice.

作者简介

Sergey Avdeev

First Sechenov Moscow State Medical University (Sechenov university); Pulmonology scientific Research Institute under Federal Medical and Biological Agency of Russian Federation

Email: serg_avdeev@list.ru
ORCID iD: 0000-0002-5999-2150
SPIN 代码: 1645-5524

MD, Dr. Sci. (Med.), Professor, Academic of the Russian Academy of Sciences

俄罗斯联邦, Moscow; Moscow

Natalia Geppe

First Sechenov Moscow State Medical University (Sechenov university)

Email: geppe@mail.ru
ORCID iD: 0000-0003-0547-3686
SPIN 代码: 9916-0204

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow

Natalia Ilina

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

编辑信件的主要联系方式.
Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN 代码: 6715-5650

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 24 Kashirskoe shosse, 115522 Moscow

Irina Demko

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

Email: demko64@mail.ru
ORCID iD: 0000-0001-8982-5292
SPIN 代码: 6520-3233

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Krasnoyarsk

Alexander Zhestkov

Samara State Medical University

Email: avzhestkov2015@yandex.ru
ORCID iD: 0000-0002-3960-830X
SPIN 代码: 2765-9617

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Samara

Olga Zaitseva

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: olga6505963@yandex.ru
ORCID iD: 0000-0003-4530-553X
SPIN 代码: 3090-4876

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow

Elena Kondyurina

Novosibirsk State Medical University

Email: condur@ngs.ru
ORCID iD: 0000-0003-3250-3107
SPIN 代码: 8665-9138

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Novosibirsk

Ilya Kukes

International Association of Clinical Pharmacologists and Pharmacists

Email: ilyakukes@gmail.com
ORCID iD: 0000-0003-1449-8711
SPIN 代码: 1166-3569

MD, Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Oksana Kurbacheva

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: kurbacheva@gmail.com
ORCID iD: 0000-0003-3250-0694
SPIN 代码: 5698-6436

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 24 Kashirskoe shosse, 115522 Moscow

Aleksandr Malakhov

First Sechenov Moscow State Medical University (Sechenov university)

Email: alexis4591m@mail.ru
ORCID iD: 0000-0002-2686-8284
SPIN 代码: 1749-0503

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow

Yury Mizernitsky

The Russian National Research Medical University named after N.I. Pirogov

Email: yulmiz@mail.ru
ORCID iD: 0000-0002-0740-1718
SPIN 代码: 6135-5260

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow

Natalya Nenasheva

Russian Medical Academy of Continuous Professional Education

Email: 1444031@gmail.com
ORCID iD: 0000-0002-3162-2510
SPIN 代码: 3363-6170

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow

Alexander Pampura

The Russian National Research Medical University named after N.I. Pirogov; Russian Medical Academy of Continuous Professional Education

Email: pampura1@mail.ru
ORCID iD: 0000-0001-5039-8473
SPIN 代码: 9722-7961

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow; Moscow

Vera Revyakina

Federal Research Center of Nutrition, Biotechnology and Food Safety

Email: 5356797@mail.ru
ORCID iD: 0000-0002-1149-7927
SPIN 代码: 4607-0540

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow

参考

  1. Global Initiative for Asthma ― GINA 2022 (ginasthma.org) [Internet]. Available from: https://ginasthma.org/gina-reports/. Accessed: 23.03.2023.
  2. Batozhargalova BT, Mizernitsky YL, Podolnaya MA. Meta-analysis of the prevalence of asthma-like symptoms and asthma in Russia (according to the results of ISAAC). Russ Bulletin Perinatol Pediatrics. 2016;61(4):59–69. (In Russ). doi: 10.21508/1027-4065-2016-61-4-59-69
  3. Chuchalin AG, Khaltaev N, Antonov NS, et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014;(9):963–974. doi: 10.2147/COPD.S67283
  4. Federal clinical guidelines “Bronchial asthma” 2021 (approved by the Russian Ministry of Health) [Internet]. Available from: https://cr.minzdrav.gov.ru/recomend/359_2. Accessed: 23.03.2023.
  5. National program. Bronchial asthma in children. Treatment strategy and prevention. 6th ed., revised and updated. Moscow: MedKom-pro; 2021. 228 p.
  6. Arkhipov VV, Aisanov ZR, Avdeev SN. Effectiveness of inhaled corticosteroids and long-acting β-agonists combinations in real clinical practice: results of a multicenter cross-sectional study in Russian patients with asthma. Pulmonologiya. 2021;31(5):613–626. (In Russ). doi: 10.18093/0869-0189-2021-31-5-613-626
  7. Baranov AA, Balabolkin II. Detskaya allergologiya (Rukovodstvo dlya vrachei). Moscow: GEOTAR-Media; 2006. 687 р. (In Russ).
  8. Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367(10):904–912. doi: 10.1056/NEJMoa1203229
  9. Heffler E, Madeira LN, Ferrando M, et al. Inhaled corticosteroids safety and adverse effects in patients with asthma. J Allergy Clin Immunol Pract. 2018;6(3):776–781. doi: 10.1016/j.jaip.2018.01.025
  10. State Register of Pharmaceutical Products (rosminzdrav.ru) [Internet]. Instructions for the use of medicines containing budesonide (Respinide, Pulmibud, Budesonide Easyhaler, Pulmicort Turbuhaler, Budenit Steri-Neb, Budesonide solution for inhalation, Pulmicort susp/for inhalation). Available from: https://grls.rosminzdrav.ru/GRLS.aspx. Accessed: 23.03.2023.
  11. State Register of Pharmaceutical Products (rosminzdrav.ru) [Internet]. Instructions for the use of medicines containing fenoterol (Fenoterol, Fenotair, Berotek, Fenavist neo, Fenoterol PSK, Beripraks, Fenoterol-aeronative). Available from: https://grls.rosminzdrav.ru/GRLS.aspx. Accessed: 23.03.2023.
  12. Csoma Z, Kharitonov SA, Balint B, et al. Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med. 2002;166(10):1345–1349. doi: 10.1164/rccm.200203-233OC
  13. Shibata A, Katsunuma T, Tomikawa M, et al. Increased leukotriene E4 in the exhaled breath condensate of children with mild asthma. Chest. 2006;130(6):1718–1722. doi: 10.1378/chest.130.6.1718
  14. Miligkos M, Bannuru RR, Alkofide H, et al. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. Ann Intern Med. 2015;163(10):756–767. doi: 10.7326/M15-1059
  15. Bérubé D, Djandji M, Sampalis JS, Becker A. Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study. Allergy Asthma Clin Immunol. 2014;10(1):21. doi: 10.1186/1710-1492-10-21
  16. Kim CK, Callaway Z, Choi J, et al. Multicenter adherence study of asthma medication for children in Korea. Allergy Asthma Immunol Res. 2019;11(2):222–230. doi: 10.4168/aair.2019.11.2.222
  17. Stanford RH, Shah M, Chaudhari SL. Clinical and economic outcomes associated with low-dose fluticasone propionate versus montelukast in children with asthma aged 4 to 11 years. Open Respir Med J. 2012;(6):37–43. doi: 10.2174/1874306401206010037
  18. Mizernitsky YL. Bronchial asthma in children. Selected issues of pediatrics. Edited by I.N. Zakharova. Moscow: Re Media; 2020. Р. 179–208. (In Russ).
  19. State Register of Pharmaceutical Products (rosminzdrav.ru) [Internet]. Instructions for the use of medicines containing montelukast. Available from: https://grls.rosminzdrav.ru/GRLS.aspx. Accessed: 23.03.2023.
  20. Marcello C, Carlo L. Asthma phenotypes: the intriguing selective intervention with Montelukast. Asthma Res Pract. 2016;(2):11. doi: 10.1186/s40733-016-0026-6
  21. Hizawa N. The understanding of asthma pathogenesis in the era of precision medicine. Allergol Int. 2023;72(1):3–10. doi: 10.1016/j.alit.2022.09.001
  22. Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med. 2007;357(18):1841–1854. doi: 10.1056/NEJMra071371
  23. Theron AJ, Steel HC, Tintinger GR, et al. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J Immunol Res. 2014;2014:608930. doi: 10.1155/2014/608930
  24. Zhang HP, Jia CE, Lv Y, et al. Montelukast for prevention and treatment of asthma exacerbations in adults: systematic review and meta-analysis. Allergy Asthma Proc. 2014;35(4):278–287. doi: 10.2500/aap.2014.35.3745
  25. Drazen JM. A step toward personalized asthma treatment. N Engl J Med. 2011;365(13):1245–1246. doi: 10.1056/NEJMe1102469
  26. Price DB, Swern A, Tozzi CA, et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy. 2006;61(6):737–742. doi: 10.1111/j.1398-9995.2006.01007.x
  27. Virchow JC, Mehta A, Ljungblad L, Mitfessel H. A subgroup analysis of the MONICA study: a 12-month, open-label study of add-on montelukast treatment in asthma patients. J Asthma. 2010;47(9):986–993. doi: 10.1080/02770903.2010.494753
  28. Dahlén SE, Malmström K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(1):9–14. doi: 10.1164/ajrccm.165.1.2010080
  29. Pearlman DS, van Adelsberg J, Philip G, et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol. 2006;97(1):98–104. doi: 10.1016/S1081-1206(10)61377-4
  30. Peroni DG, Pescollderungg L, Sandri M, et al. Time-effect of montelukast on protection against exercise-induced bronchoconstriction. Respir Med. 2011;105(12):1790–1797. doi: 10.1016/j.rmed.2011.08.007
  31. De Benedictis FM, del Giudice MM, Forenza N, et al. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J. 2006;28(2):291–295. doi: 10.1183/09031936.06.00020606
  32. Peters-Golden M, Swern A, Bird SS, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006;27(3):495–503. doi: 10.1183/09031936.06.00077205
  33. Sutherland ER, Camargo CA, Busse WW, et al. Comparative effect of body mass index on response to asthma controller therapy. Allergy Asthma Proc. 2010;31(1):20–25. doi: 10.2500/aap.2010.31.3307
  34. Ryabova SE, Mizernitsky YU. Bronchial asthma and obesity in children. Pediatricians practice. 2022;(3):3–6. (In Russ).
  35. Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007;175(8): 783–790. doi: 10.1164/rccm.200511-1746OC
  36. Price D, Popov TA, Bjermer L, et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol. 2013;131(3):763–771. doi: 10.1016/j.jaci.2012.12.673
  37. Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med. 2005;171(4): 315–322. doi: 10.1164/rccm.200407-894OC
  38. Nagao M, Ikeda M, Fukuda N, et al. Early control treatment with montelukast in preschool children with asthma: a randomized controlled trial. Allergol Int. 2018;67(1):72–78. doi: 10.1016/j.alit.2017.04.008
  39. Schuler CF, Montejo JM. Allergic rhinitis in children and adolescents. Immunol Allergy Clin North Am. 2021;41(4):613–625. doi: 10.1016/j.iac.2021.07.010
  40. Philip G, Hustad CM, Malice MP, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol. 2009;124(4):699–706.e8. doi: 10.1016/j.jaci.2009.08.011
  41. Sansing-Foster V, Haug N, Mosholder A, et al. Risk of psychiatric adverse events among montelukast users. J Allergy Clin Immunol Pract. 2021;9(1):385–393.e12. doi: 10.1016/j.jaip.2020.07.052
  42. Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol. 2009;44(6):568–579. doi: 10.1002/ppul.21018
  43. Paljarvi T, Forton J, Luciano S, et al. Analysis of neuropsychiatric diagnoses after montelukast initiation. JAMA Netw Open. 2022; 5(5):e2213643. doi: 10.1001/jamanetworkopen.2022.13643
  44. Sentinel Initiative [Internet]. Neuropsychiatric Events Following Montelukast Use: A Propensity Score Matched Analysis. Available from: https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/neuropsychiatric-events-following-montelukast-use-propensity. Accessed: 23.03.2023.
  45. U.S. Food and Drug Administration (fda.gov) [Internet]. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug. Accessed: 23.03.2023.
  46. Marques CF, Marques MM, Justino GC. The mechanisms underlying montelukast’s neuropsychiatric effects: new insights from a combined metabolic and multiomics approach. Life Sci. 2022; (310):121056. doi: 10.1016/j.lfs.2022.121056
  47. Blackman JA, Gurka MJ. Developmental and behavioral comorbidities of asthma in children. J Dev Behav Pediatr. 2007;28(2): 92–99. doi: 10.1097/01.DBP.0000267557.80834.e5
  48. Easter G, Sharpe L, Hunt CJ. Systematic review and meta-analysis of anxious and depressive symptoms in caregivers of children with asthma. J Pediatr Psychol. 2015;40(7):623–632. doi: 10.1093/jpepsy/jsv012
  49. Wallerstedt SM, Brunlöf G, Sundström A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf. 2009;18(9):858–864. doi: 10.1002/pds.1794
  50. Mizernitskiy YL. Pathogenetic reasoning for use of monteleukast (singlon) in acute respiratory viral infections with broncho-obstructive syndrome in infants and preschool age children. Russ Bulletin Perinatol Pediatrics. 2020;65(6):129–132. (In Russ). doi: 10/21508/1027-4065/2020-65-6-129-132
  51. Harding TW, Harding AG. Role of montelukast in management of episodic viral wheeze. J Paediatr Child Health. 2017;53(12): 1240–1241. doi: 10.1111/jpc.13797
  52. Williams B, Noonan G, Reiss TF, et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy. 2001;31(6):845–854. doi: 10.1046/j.1365-2222.2001.01085.x
  53. Storms W, Michele TM, Knorr B, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged ≥6 years. Clin Exp Allergy. 2001;31(10):77–87. doi: 10.1046/j.1365-2222.2001.00969.x

版权所有 © Pharmarus Print Media, 2023

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
##common.cookie##